NASDAQ:CDMO Avid Bioservices - CDMO Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Avid Bioservices, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $18.76 +0.57 (+3.13%) (As of 03/31/2023 12:00 AM ET) Add Compare Share Share Today's Range$18.30▼$18.9950-Day Range$13.82▼$18.7952-Week Range$11.30▼$22.38Volume477,714 shsAverage Volume889,065 shsMarket Capitalization$1.17 billionP/E Ratio11.30Dividend YieldN/APrice Target$22.33 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Avid Bioservices MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside19.0% Upside$22.33 Price TargetShort InterestBearish9.27% of Shares Sold ShortDividend StrengthN/ASustainability-0.96Upright™ Environmental ScoreNews Sentiment0.83Based on 3 Articles This WeekInsider TradingSelling Shares$493,266 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.04) to $0.10 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.09 out of 5 starsMedical Sector513th out of 1,004 stocksPharmaceutical Preparations Industry240th out of 489 stocks 2.5 Analyst's Opinion Consensus RatingAvid Bioservices has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $22.33, Avid Bioservices has a forecasted upside of 19.0% from its current price of $18.76.Amount of Analyst CoverageAvid Bioservices has only been the subject of 2 research reports in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted9.27% of the outstanding shares of Avid Bioservices have been sold short.Short Interest Ratio / Days to CoverAvid Bioservices has a short interest ratio ("days to cover") of 10, which indicates bearish sentiment.Change versus previous monthShort interest in Avid Bioservices has recently increased by 22.62%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAvid Bioservices does not currently pay a dividend.Dividend GrowthAvid Bioservices does not have a long track record of dividend growth. Previous Next 4.5 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAvid Bioservices has received a 68.99% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Biopharmaceuticals", "Clinical research services", and "Process engineering services for the pharmaceutical industry" products. See details.Environmental SustainabilityThe Environmental Impact score for Avid Bioservices is -0.96. Previous Next 2.7 News and Social Media Coverage News SentimentAvid Bioservices has a news sentiment score of 0.83. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.56 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Avid Bioservices this week, compared to 1 article on an average week.Search InterestOnly 5 people have searched for CDMO on MarketBeat in the last 30 days. This is a decrease of -17% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Avid Bioservices to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Avid Bioservices insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $493,266.00 in company stock.Percentage Held by InsidersOnly 1.86% of the stock of Avid Bioservices is held by insiders.Percentage Held by Institutions98.95% of the stock of Avid Bioservices is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Avid Bioservices are expected to grow in the coming year, from ($0.04) to $0.10 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Avid Bioservices is 11.30, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 119.98.Price to Earnings Ratio vs. SectorThe P/E ratio of Avid Bioservices is 11.30, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 79.52.Price to Book Value per Share RatioAvid Bioservices has a P/B Ratio of 6.34. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Avid Bioservices (NASDAQ:CDMO) StockAvid Bioservices, Inc. engages in the commercial manufacturing. The firm focuses on the biopharmaceutical products derived from mammalian cell culture for culture for biotechnology and pharmaceutical companies. It specializes in clinical and commercial product manufacturing, purification, bulk packaging, stability testing and regulatory submissions and support. The company was founded on June 3, 1981 and is headquartered in Tustin, CA.Read More Receive CDMO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Avid Bioservices and its competitors with MarketBeat's FREE daily newsletter. Email Address CDMO Stock News HeadlinesMarch 14, 2023 | marketbeat.comMonoclonal Antibodies? Avid Bioservices surges 32% on Blowout Q3Avid Bioservices Inc. (NASDAQ: CDMO) is a contract development and manufacturing organization (CDMO) that specializes in producing monoclonal antibodies,March 14, 2023 | msn.comKeybanc Upgrades Avid Bioservices (CDMO)April 1, 2023 | Investorplace Media (Ad)5 Stocks to Buy ImmediatelyAmerica’s #1 stock picker issues 5 buy alerts – one of which is positioned to be the next Tesla. Just click to claim your copy. March 14, 2023 | benzinga.comAvid Bioservices shares are trading higher after the company reported better-than-expected Q3 adjusted EPS and sales results.March 14, 2023 | marketwatch.comAvid Bioservices Shares Soar on 3Q ResultsMarch 14, 2023 | finance.yahoo.comAvid Bioservices, Inc. (NASDAQ:CDMO) Q3 2023 Earnings Call TranscriptMarch 14, 2023 | finance.yahoo.comWhy Avid Bioservices Stock Is Surging TodayMarch 14, 2023 | finance.yahoo.comQ3 2023 Avid Bioservices Inc Earnings CallApril 1, 2023 | Investorplace Media (Ad)5 Stocks to Buy ImmediatelyAmerica’s #1 stock picker issues 5 buy alerts – one of which is positioned to be the next Tesla. Just click to claim your copy. March 14, 2023 | finance.yahoo.comDeclining Stock and Solid Fundamentals: Is The Market Wrong About Avid Bioservices, Inc. (NASDAQ:CDMO)?March 10, 2023 | finance.yahoo.comSteer Clear Of These 4 Toxic Stocks to Avoid LossesMarch 6, 2023 | finance.yahoo.comAvid Bioservices to Report Financial Results for Third Quarter of Fiscal Year 2023 After Market Close on March 13, 2023February 9, 2023 | marketwatch.comPharmaceutical CXO Market Share : Industry Trends, Growth, Size and Segmentation by 2023 to 2029January 31, 2023 | seekingalpha.comLaughing Water Capital - Avid Bioservices: Recession Resistant Cash Flows And ~200% UpsideJanuary 22, 2023 | nypost.comAs Vancouver decriminalizes hard drugs, this avid user is risking arrest to sell crack, heroin and meth out of his ‘Drugs Store’December 9, 2022 | seekingalpha.comAvid Bioservices: Production Expansion Capex And High Costs Are Temporary IssuesDecember 6, 2022 | seekingalpha.comAvid Bioservices, Inc. (CDMO) Q2 2023 Earnings Call TranscriptNovember 30, 2022 | finance.yahoo.comAvid Bioservices to Report Financial Results for Second Quarter of Fiscal Year 2023 After Market Close on December 6, 2022November 17, 2022 | finance.yahoo.comAvid Bioservices (NASDAQ:CDMO) jumps 12% this week, though earnings growth is still tracking behind five-year shareholder returnsNovember 16, 2022 | finance.yahoo.comAvid Bioservices Appoints Oksana Lukash as Vice President, PeopleNovember 5, 2022 | fool.comAvid Bioservices, Inc. (NASDAQ: CDMO)October 17, 2022 | finance.yahoo.comDoes Avid Bioservices (CDMO) Have the Potential to Rally 61% as Wall Street Analysts Expect?October 5, 2022 | finance.yahoo.comAre Strong Financial Prospects The Force That Is Driving The Momentum In Avid Bioservices, Inc.'s NASDAQ:CDMO) Stock?September 19, 2022 | markets.businessinsider.comRBC Capital Reaffirms Their Buy Rating on Avid Bioservices (CDMO)September 10, 2022 | nasdaq.comHere's Why Avid Bioservices (NASDAQ:CDMO) Has A Meaningful Debt BurdenSeptember 8, 2022 | finance.yahoo.comWe Ran A Stock Scan For Earnings Growth And Avid Bioservices (NASDAQ:CDMO) Passed With EaseSeptember 6, 2022 | finance.yahoo.comAvid Bioservices Reports Financial Results for First Quarter Ended July 31, 2022 and Recent DevelopmentsSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive CDMO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Avid Bioservices and its competitors with MarketBeat's FREE daily newsletter. Email Address CDMO Company Calendar Last Earnings12/07/2021Today4/01/2023Fiscal Year End4/30/2023Next Earnings (Estimated)7/05/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CDMO CUSIPN/A CIK704562 Webwww.avidbio.com Phone(714) 508-6100Fax714-838-5817Employees252Year FoundedN/APrice Target and Rating Average Stock Price Forecast$22.33 High Stock Price Forecast$25.00 Low Stock Price Forecast$20.00 Forecasted Upside/Downside+19.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)$1.66 Trailing P/E Ratio11.30 Forward P/E RatioN/A P/E GrowthN/ANet Income$127.67 million Net Margins82.78% Pretax Margin1.52% Return on Equity1.70% Return on Assets0.69% Debt Debt-to-Equity Ratio0.77 Current Ratio1.52 Quick Ratio1.00 Sales & Book Value Annual Sales$119.60 million Price / Sales9.81 Cash Flow$0.37 per share Price / Cash Flow51.33 Book Value$2.96 per share Price / Book6.34Miscellaneous Outstanding Shares62,550,000Free Float61,384,000Market Cap$1.17 billion OptionableOptionable Beta1.76 Key ExecutivesNicholas S. GreenPresident, Chief Executive Officer & DirectorRichard A. RichieriChief Operating OfficerDaniel Ryan HartChief Financial OfficerNick FergusonExecutive Director-Information TechnologyMark R. ZiebellSecretary, Vice President & General CounselKey CompetitorsMoonLake ImmunotherapeuticsNASDAQ:MLTXDeciphera PharmaceuticalsNASDAQ:DCPHProtagonist TherapeuticsNASDAQ:PTGXKeros TherapeuticsNASDAQ:KROSGeronNASDAQ:GERNView All CompetitorsInsiders & InstitutionsDaniel R HartSold 5,000 sharesTotal: $95,000.00 ($19.00/share)Richard B HancockSold 5,000 sharesTotal: $82,950.00 ($16.59/share)Lakewood Asset Management LLCBought 2,530 shares on 3/1/2023Ownership: 0.004%Voya Investment Management LLCSold 863 shares on 2/28/2023Ownership: 0.038%Macquarie Group Ltd.Sold 26,847 shares on 2/21/2023Ownership: 0.139%View All Insider TransactionsView All Institutional Transactions CDMO Stock - Frequently Asked Questions Should I buy or sell Avid Bioservices stock right now? 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Avid Bioservices in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CDMO shares. View CDMO analyst ratings or view top-rated stocks. What is Avid Bioservices' stock price forecast for 2023? 2 analysts have issued twelve-month target prices for Avid Bioservices' shares. Their CDMO share price forecasts range from $20.00 to $25.00. On average, they expect the company's share price to reach $22.33 in the next year. This suggests a possible upside of 19.0% from the stock's current price. View analysts price targets for CDMO or view top-rated stocks among Wall Street analysts. How have CDMO shares performed in 2023? Avid Bioservices' stock was trading at $13.77 on January 1st, 2023. Since then, CDMO shares have increased by 36.2% and is now trading at $18.76. View the best growth stocks for 2023 here. Are investors shorting Avid Bioservices? Avid Bioservices saw a increase in short interest in March. As of March 15th, there was short interest totaling 5,800,000 shares, an increase of 22.6% from the February 28th total of 4,730,000 shares. Based on an average daily trading volume, of 582,300 shares, the short-interest ratio is presently 10.0 days. View Avid Bioservices' Short Interest. When is Avid Bioservices' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, July 5th 2023. View our CDMO earnings forecast. How were Avid Bioservices' earnings last quarter? Avid Bioservices, Inc. (NASDAQ:CDMO) posted its earnings results on Tuesday, December, 7th. The biopharmaceutical company reported $0.06 EPS for the quarter, topping analysts' consensus estimates of $0.02 by $0.04. The biopharmaceutical company had revenue of $26.11 million for the quarter, compared to analyst estimates of $25 million. Avid Bioservices had a trailing twelve-month return on equity of 1.70% and a net margin of 82.78%. During the same period in the prior year, the company posted $0.01 earnings per share. What ETFs hold Avid Bioservices' stock? ETFs with the largest weight of Avid Bioservices (NASDAQ:CDMO) stock in their portfolio include Invesco Dynamic Biotechnology & Genome ETF (PBE), Franklin Genomic Advancements ETF (HELX), Invesco S&P SmallCap Health Care ETF (PSCH), SPDR S&P Biotech ETF (XBI), Direxion Daily S&P Biotech Bull 3x Shares (LABU), iShares Micro-Cap ETF (IWC) and Syntax Stratified SmallCap ETF (SSLY).Invesco S&P SmallCap 600 Equal Weight ETF (EWSC). When did Avid Bioservices' stock split? Avid Bioservices shares reverse split on Monday, July 10th 2017. The 1-7 reverse split was announced on Friday, July 7th 2017. The number of shares owned by shareholders was adjusted after the market closes on Friday, July 7th 2017. An investor that had 100 shares of stock prior to the reverse split would have 14 shares after the split. What guidance has Avid Bioservices issued on next quarter's earnings? Avid Bioservices updated its FY 2023 earnings guidance on Monday, March, 13th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $145.00 million-$150.00 million, compared to the consensus revenue estimate of $146.57 million. What is Roger Lias' approval rating as Avid Bioservices' CEO? 5 employees have rated Avid Bioservices Chief Executive Officer Roger Lias on Glassdoor.com. Roger Lias has an approval rating of 49% among the company's employees. This puts Roger Lias in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. 63.0% of employees surveyed would recommend working at Avid Bioservices to a friend. What other stocks do shareholders of Avid Bioservices own? Based on aggregate information from My MarketBeat watchlists, some companies that other Avid Bioservices investors own include Array Technologies (ARRY), Anavex Life Sciences (AVXL), Inovio Pharmaceuticals (INO), Advanced Micro Devices (AMD), Dynavax Technologies (DVAX), Micron Technology (MU), QUALCOMM (QCOM), NVIDIA (NVDA), Novavax (NVAX) and Pfizer (PFE). What is Avid Bioservices' stock symbol? Avid Bioservices trades on the NASDAQ under the ticker symbol "CDMO." How do I buy shares of Avid Bioservices? Shares of CDMO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Avid Bioservices' stock price today? One share of CDMO stock can currently be purchased for approximately $18.76. How much money does Avid Bioservices make? Avid Bioservices (NASDAQ:CDMO) has a market capitalization of $1.17 billion and generates $119.60 million in revenue each year. The biopharmaceutical company earns $127.67 million in net income (profit) each year or $1.66 on an earnings per share basis. How many employees does Avid Bioservices have? The company employs 252 workers across the globe. How can I contact Avid Bioservices? Avid Bioservices' mailing address is 2642 Michelle Drive Suite 200, TUSTIN CA, 92780. The official website for the company is www.avidbio.com. The biopharmaceutical company can be reached via phone at (714) 508-6100, via email at sdiaz@vidasp.com, or via fax at 714-838-5817. This page (NASDAQ:CDMO) was last updated on 4/1/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.